NCT06969430View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

November 30, 2031

Study Completion Date

November 30, 2031

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Debio 1562M

Administered as intravenous (IV) infusion

Trial Locations (7)

14203

NOT_YET_RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

43210

RECRUITING

The Ohio Sate University, Columbus

49546

RECRUITING

START Midwest, Grand Rapids

60637

RECRUITING

University of Chicago, Chicago

77030

RECRUITING

MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

33612-9416

RECRUITING

Moffitt Cancer Center and Research Institute Hospital, Tampa

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY